<DOC>
	<DOCNO>NCT03013491</DOCNO>
	<brief_summary>The purpose first-in-human study CX-072 characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) antitumor activity CX-072 administer intravenously ( IV ) single agent combination ipilimumab vemurafenib adult subject advance recurrent solid tumor lymphomas . PROCLAIM-001 : PRObody CLinical Assessment In Man CX-072 clinical trial 001 CX-072 Probodyâ„¢ therapeutic direct PD-L1 ( program cell death ligand 1 ) . Probody therapeutic proteolytically-activatable antibody ( Abs ) design widen therapeutic index minimize drug interaction normal tissue retain anti-tumor activity . Probody therapeutic `` mask '' attenuate bind target healthy tissue become `` unmasked '' tumor microenvironment tumor-specific protease activity . PROBODY trademark CytomX Therapeutics , Inc .</brief_summary>
	<brief_title>PROCLAIM-072 : A Trial Find Safe Active Doses Investigational Drug CX-072 Patients With Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically confirm diagnosis metastatic advance unresectable tumor progress standard therapy 2 . Agreement provide mandatory archival tissue fresh biopsy . 3 . At least 18 year age . 1 . Prior therapy chimeric antigen receptor ( CAR ) Tcell contain regimen . 2 . History severe allergic anaphylactic reaction human monoclonal antibody therapy know hypersensitivity Probody therapeutic . 3 . Active history uveal , mucosal , ocular melanoma . Human immunodeficiency virus ( HIV ) acquire immune deficiency syndrome ( AIDS ) relate illness , chronic hepatitis B C. 4 . History current active autoimmune disease , include limited inflammatory bowel disease , rheumatoid arthritis , autoimmune thyroiditis , autoimmune hepatitis , systemic sclerosis , systemic lupus erythematosus , autoimmune vasculitis , autoimmune neuropathy , type 1 insulin dependent diabetes mellitus . 5 . History syndrome medical condition ( ) require systemic steroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication . 6 . History allogeneic tissue/solid organ transplant , prior stem cell bone marrow transplant . 7 . Chemotherapy , biochemotherapy , radiation immunotherapy investigational treatment within 30 day prior receive study drug . 8 . Major surgery ( require general anesthesia ) within 3 month minor surgery ( exclude biopsy conduct local/topical anesthesia ) gamma knife treatment within 14 day ( adequate healing ) administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>checkpoint inhibitor</keyword>
	<keyword>monotherapy</keyword>
	<keyword>combination</keyword>
	<keyword>PD-L1</keyword>
	<keyword>CTLA-4</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>BRAF</keyword>
	<keyword>PROCLAIM</keyword>
	<keyword>CX-072</keyword>
	<keyword>PROCLAIM-072</keyword>
</DOC>